Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

Update: 2023-08-10

Description

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00145-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Cathy Lu on intestinal ultrasound for assessing and monitoring Crohn's disease small bowel strictures

2024-12-1211:15

$Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis$

Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis

2024-11-0614:42

Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease

2024-11-0134:15

Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

2024-07-3118:23

Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy

2024-07-0125:05

Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS

2024-05-1723:16

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

2024-05-0719:55

Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa

2024-04-2220:54

Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake

2024-03-1216:39

Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity

2024-03-0123:19

Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region

2023-12-1914:40

Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy

2023-11-2914:45

Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease

2023-10-1216:19

Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction

2023-09-1316:31

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

2023-08-1014:29

Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease

2023-07-1217:41

Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis

2023-06-0712:48

Adelina Artenie on the incidence of HIV and HCV in people who inject drugs

2023-05-1017:15

Johan Burisch on the costs of inflammatory bowel disease in high-income settings

2023-04-1220:00

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

2023-02-0821:30

00:00

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

#box-pro-ellipsis-173453389410899{-webkit-line-clamp:2;}Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

The Lancet Group

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis